Halda Therapeutics founder Craig Crews and CSO Kat Kayser-Bricker

PRO­TACs to RIP­TACs: Arv­inas founder snags $76M for next bet, Hal­da Ther­a­peu­tics

A leader in the pro­tein degra­da­tion space, Yale’s Craig Crews, is back with an­oth­er biotech, Hal­da Ther­a­peu­tics.

On Tues­day, the start­up an­nounced $76 mil­lion in fund­ing to take for­ward a new tech­nol­o­gy out of Crews’ lab, called RIP­TACs, or Reg­u­lat­ed In­duced Prox­im­i­ty TAr­get­ing Chimeras.

The 26-em­ploy­ee start­up emerged from his decades-long work on het­er­ob­i­func­tion­al mol­e­cules, he told End­points News, dat­ing back to his 2001 pa­per on PRO­TACs, which formed the foun­da­tion for Arv­inas in 2013.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.